SubHero Banner

Exkivity(mobocertinib) – New orphan drug approval

On September 15, 2021, Takeda announced the FDA approval of Exkivity (mobocertinib), for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDAapproved test, whose disease has progressed on or after platinum-based chemotherapy.

Download PDF